Hikma Pharmaceuticals (HKMPF) to Post Quarterly Earnings on Thursday

Hikma Pharmaceuticals (OTCMKTS:HKMPF) will likely be announcing its resultson Thursday, August 6th. Analysts expect Hikma Pharmaceuticals to post earnings of $1.10 per share and revenue of $1.7030 billion for the quarter.

Hikma Pharmaceuticals Price Performance

Shares of OTCMKTS:HKMPF opened at $21.56 on Thursday. Hikma Pharmaceuticals has a 1-year low of $16.34 and a 1-year high of $26.38. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.82 and a quick ratio of 1.06. The business has a 50-day moving average price of $19.99 and a two-hundred day moving average price of $19.42.

Analysts Set New Price Targets

Separately, Citigroup initiated coverage on shares of Hikma Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.